ESTRO 2021 Abstract Book

S727

ESTRO 2021

Results: Data collected locally over 10 months, show a total of 411 palliative radiotherapy treatments were recorded. 84 of these treatments (20%) were on the Urgent + pathway to 71 individual patients. Of the 84 treatments, 87% did meet the Urgent + (four working day) pathway. The other 13% had delays due factors such as unplanned downtime, rescan required or too ill to attend. Patient reported outcome data has also been collected following radiotherapy treatment for this patient cohort and is seen in table 1. Approximately 40% of treatments had benefits reported by patients in either their condition through pain relief or overall improvement in their quality of life. Average survival time post treatment was 1.9 months, therefore by delivering the treatment in a shorter time frame the patients were able to benefit from some symptom control towards their end of life. Data can be extracted to complete RCR audits on dose/fractionation and 30 day mortality 2 . Conclusion Conclusion: We have developed and implemented a rapid pathway, with defined criteria and auditable referrals, for patients who required palliative radiotherapy in a more timely way. This is embedded within the palliative clinical protocol and now standard practice within the department. By monitoring this pathway we are able to assess referral patterns and link patient outcomes to ensure appropriate referrals are in place for both patients’ needs and the service demands. PD-0889 Hemostatic radiotherapy for bleeding control in gynecological tumors M. Valero 1 , V.J. Duque 2 , J.A. Domínguez 3 , T. Muñoz 3 1 Hospital Universitario Ramón y Cajal, Oncología Radioterapia, Madrid, Spain; 2 Hospital Universitario Ramón y Cajal, Oncología Radioterapica, Madrid, Spain; 3 Hospital Universitario Ramón y Cajal, Oncología Radioterápica, Madrid, Spain Purpose or Objective The aim of this study was to assess the effectiveness of radiotherapy for control of tumoral bleeding. The secondary objectives were to determine if any treatment schedule had better results in bleeding control, analyze differences between the location of the primary and histological subtype and assess differences between hemoglobin levels before and after treatment. Materials and Methods This is a retrospective study were we have carried out a descriptive analysis of 44 consecutive patients diagnosed with gynecological cancer treated with hemostatic radiotherapy for inoperable, locally advanced, recurrent or metastatic disease from 2016 to 2020. The most commonly prescribed RT doses were 37.5Gy in 15 fractions, 30 Gy in 10 fractions, 20 Gy in 5 fractions and 8 Gy in a single fraction. All data were analyzed using SPSS 20.0 (2011) statistical analysis. Data were compared by X2 test and Fisher’s exact test. OS was analyzed using Kaplan-Meier. Results We analyzed a total of 44 patients with a mean age at diagnosis of 81 years (range 53-97). There were 11 patients with cervical cancer (25%), 22 with endometrial cancer (50%), 4 with vaginal cancer (9.1%), 6 with ovarian cancer (13.6%), and 1 with sarcoma of the uterus (2.3%). Among the cervical cancer patients seven (63.6%) had squamous cell carcinoma, three adenocarcinoma (27.1%) and one with other histology (9.1%). Regarding endometrial cancer, 9 had endometrioid adenocarcinoma (45%), 7 serous carcinoma (35%) and 4 other histology (20%). 24 patients (54.5%) had metastases at diagnosis. Median follow-up was 10.7 months. The overall primary bleeding control rate was 100%. There was not improvement in hemoglobin levels after RT although levels remained stable (11.3 preRT vs. 11.2 postRT). Five patients (18.2%) presented re-bleeding after RT and median time from primary treatment to re-bleeding was 13.4 months. No differences in the incidence of re-bleeding were found in terms of prescribed fractionations ( p = 0.76), primary tumor location ( p = 0.17) or histological subtype. The one year overall survival rate in this population was 31.3%. Conclusion Palliative RT with hemostatic intent is highly effective for bleeding control in gynecological cancer. Shorter radiotherapy regimens showed equal efficacy and duration of response than longer radiotherapy schedules and